


**REMARKS**

Please amend claims 1, 4, 8-10, 14, 16 and 25. Please cancel claims 11-13 and 17 without prejudice or disclaimer. The amended claims are fully supported by the specification as filed and do not add new matter. Claims 1, 8-10, 16 and 25 were amended to recite an adenovirus particle comprising a fiber from a subgroup D adenovirus wherein the subgroup D adenovirus is selected from serotypes which include adenovirus serotype 37. Support for the amendment can be found in, for example, Example 18 of the specification as filed. Claim 4 was amended to reflect the selection of the subgroup C adenovirus serotype 5. The dependency of claim 14 was amended. Accordingly, entry of the amended claims is respectfully requested.

No fee is deemed necessary with the filing of this paper. However, the Commissioner is hereby authorized to charge any fees that may be due in connection with the filing of this paper, or credit any overpayment to Deposit Account No. 07-1896, referencing the above-identified docket number.

Respectfully submitted,

Date: November 7, 2008

  
\_\_\_\_\_  
Lisa A. Haile, J.D., Ph.D.  
Registration No.: 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

DLA PIPER LLP (US)  
4365 Executive Drive, Suite 1100  
San Diego, CA 92121-2133  
USPTO Customer No.: 28213